Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bionomics acquires Eclipse Therapeutics
Eclipse develops drug candidates, such as ET101 that targets cancer stem cells (CSCs), which are the seeds at the root of cancer. Bionomics CEO and managing director Deborah
Eclipse develops drug candidates, such as ET101 that targets cancer stem cells (CSCs), which are the seeds at the root of cancer. Bionomics CEO and managing director Deborah
Under the agreement, Oxford Pharmascience will develop and commercialize various re-formulated statins, using the generic cholesterol-lowering drugs, atorvastatin and simvastatin. In addition, Oxford has established the feasibility of
The migraine treatment drug candidate, MSRX-202, leverages MonoSol PharmFilm technology in a combination product that includes rizatriptan for the treatment of migraine pain and ondansetron for the treatment
DARA plans to launch Gelclair, a topical gel used to coat and protect the oral cavity to reduce pain, in the first quarter of 2013. DARA chief executive
Reverse-vine is an extract which contains stilbenes, natural compounds produced by the grapevine as part of their defense system including resveratrol, reports naturalproductsinside. In addition, the product includes
Patients with metastatic stage IIIB, or stage IV, or recurrent squamous cell carcinoma of the lung who are chemotherapy naïve for their metastatic or recurrent cancer were treated
Cenergy Nutrition Line of Products will be exhibited between 27-30 September, according to the company. Bill Chaaban CEO said the Cenergy line is a big part of the
The error came to light when intermediate acting Hypurin Porcine Isophane Insulin 100 IU/ml cartridges carton got into the production line for the short acting Hypurin Porcine Neutral
As per the agreement, Panacea Biotec will involve in product development and manufacturing, while Osmotica will lead product registration, legal matters as well as commercialization. The collaboration products
According to the agreement, Pulmatrix will receive $1.4m in upfront and milestone-driven funding for the effort from the CFFT, along with introductions to cystic fibrosis academic researchers and